Latest Us Healthcare Market News

Adherium Limited has successfully closed the institutional portion of its entitlement offer, increasing the raise to $4.492 million due to robust demand. The company now invites retail shareholders to participate as it advances its digital respiratory health solutions.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Artrya Limited has submitted a pivotal FDA 510(k) application for its AI-powered Salix® Coronary Plaque module, aiming for clearance in Q3 2025 and a lucrative US commercial launch.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Artrya Limited reports solid progress on its FDA 510(k) application and secures a A$5 million capital raise, positioning itself for imminent commercial rollout in the US healthcare sector.